The incidence of heart failure (HF) continues to increase in the Western world and HF related morbidity and mortality remain unacceptably high. Advances in understanding the molecular mechanisms that are associated with cardiac failure have offered a number of important targets for intervention. Two critical abnormalities in failing cardiomyocytes are: 1) an abnormal sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) pump function and 2) decreased expression of SERCA2a. The importance of reduced SERCA2a expression in HF is documented in many studies utilizing experimental animal models and restoration of SERCA2a by gene transfer significantly rescues HF phenotype and increases animal survival. Our group has targeted the reduced expression of SERCA2a by delivering intracoronary adeno-associated vector type 1 encoding SERCA2a (AAV1.SERCA2a) in patients with heart failure. During the previous funding period, our group found that post- translational modifications (PTMs) of SERCA2a can significantly affect the function of this pump. We discovered that the levels and activity of SERCA2a in cardiomyocytes are modulated by small ubiquitin-like modifiers type 1 (SUMO-1). Reduced SUMO-1 levels and decreased SERCA2a SUMOylation were found in failing human myocardium. In the first four years of our proposal, we showed that in murine studies, AAV- mediated SUMO-1 gene delivery significantly improved SERCA2a's levels, cardiac function and increased mouse survival in pressure overload-induced HF. We also found that SUMO-1 gene transfer improved contractility and prevented left ventricular dilation in failing pig hearts. SUMOylation was found to be a critical PTM that regulates SERCA2a function. There is also growing evidence that aside from SUMOylation other PTMs such as oxidation, methylation, nitration, phosphorylation and acetylation occur in cardiac cells. The crosstalk and selectivity of different lysine PTMs of SERCA2a could be an important mechanism for cells to respond to different stimuli in a time-dependent fashion. Our recent findings show that SERCA2a SUMOylation is closely linked to lysine acetylation/deacetylation pathways. First, SERCA2a SUMOylation is decreased in HF while acetylation is increased in the setting of HF. Second, SERCA2a acetylation negatively impacts SERCA2a's function. Third, our preliminary data show that the reduction of acetylation is accompanied by increased SUMOylation of SERCA2a. These data suggest that there is a balance between acetylation and SUMOylation of SERCA2a, which is altered in HF. The major hypothesis of our proposal is that SERCA2a acetylation decreases SERCA2a function and reduces SUMOylation of SERCA2a leading to worsening cardiac function in the setting of HF. Achieving these aims will provide new insights into the mechanisms of lysine-mediated SERCA2a regulation in the setting of HF. This study will provide a novel strategy for manipulating SERCA2a post-translational modifications that may ultimately lead to novel therapeutic agents.

Public Health Relevance

Heart failure is associated with abnormal calcium cycling which is related to a decrease in expression and a deficiency in the cardiac Sarcoplasmic Reticulum Calcium ATPase pump (SERCA2a). We have found that in heart failure, acetylation of SERCA2a is increased resulting in worsening cardiac function. In this proposal, we will test whether inhibition of SERCA2a hyper-acetylation in the setting of heart failure improves SERCA2a function thereby enhancing cardiac function.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL117505-08
Application #
10001565
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Schwartz, Lisa
Project Start
2013-09-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ceholski, Delaine K; Turnbull, Irene C; Kong, Chi-Wing et al. (2018) Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 119:147-154
Oh, Jae Gyun; Watanabe, Shin; Lee, Ahyoung et al. (2018) miR-146a Suppresses SUMO1 Expression and Induces Cardiac Dysfunction in Maladaptive Hypertrophy. Circ Res 123:673-685
Jeong, Dongtak; Yoo, Jimeen; Lee, Philyoung et al. (2018) miR-25 Tough Decoy Enhances Cardiac Function in Heart Failure. Mol Ther 26:718-729
Watanabe, Shin; Fish, Kenneth; Bonnet, Guillaume et al. (2018) Echocardiographic and hemodynamic assessment for predicting early clinical events in severe acute mitral regurgitation. Int J Cardiovasc Imaging 34:171-175
Hammoudi, Nadjib; Watanabe, Shin; Bikou, Olympia et al. (2018) Speckle-Tracking Echocardiographic Strain Analysis Reliably Estimates Degree of Acute LV Unloading During Mechanical LV Support by Impella. J Cardiovasc Transl Res :
Watanabe, Shin; Leonardson, Lauren; Hajjar, Roger J et al. (2017) Cardiac Gene Delivery in Large Animal Models: Antegrade Techniques. Methods Mol Biol 1521:227-235
Guénantin, Anne-Claire; Briand, Nolwenn; Capel, Emilie et al. (2017) Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. Diabetes 66:1470-1478
Yoo, Jimeen; Hajjar, Roger J; Jeong, Dongtak (2017) Generation of Efficient miRNA Inhibitors Using Tough Decoy Constructs. Methods Mol Biol 1521:41-53
Aguero, Jaume; Hadri, Lahouaria; Hammoudi, Nadjib et al. (2017) Inhaled Gene Transfer for Pulmonary Circulation. Methods Mol Biol 1521:339-349
Ceholski, Delaine K; Turnbull, Irene C; Pothula, Venu et al. (2017) CXCR4 and CXCR7 play distinct roles in cardiac lineage specification and pharmacologic ?-adrenergic response. Stem Cell Res 23:77-86

Showing the most recent 10 out of 50 publications